HELX PE Ratio & Valuation, Is HELX Overvalued

Performance Decomposition

AI Analysis

Market capitalization of HELX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of HELX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is HELX currently overvalued or undervalued?

Franklin Genomic Advancements ETF (HELX) is now in the Fair zone, suggesting that its current forward PS ratio of NaN is considered Fairly compared with the five-year average of --. The fair price of Franklin Genomic Advancements ETF (HELX) is between -- to -- according to relative valuation method.

What is Franklin Genomic Advancements ETF (HELX) fair value?

HELX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Franklin Genomic Advancements ETF (HELX) is between -- to -- according to relative valuation method.

How does HELX's valuation metrics compare to the industry average?

The average P/S ratio for HELX's competitors is 0.00, providing a benchmark for relative valuation. Franklin Genomic Advancements ETF Corp (HELX) exhibits a P/S ratio of --, which is 0% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

What is the current P/B ratio for Franklin Genomic Advancements ETF (HELX) as of Mar 05 2026?

As of Mar 05 2026, Franklin Genomic Advancements ETF (HELX) has a P/B ratio of NaN. This indicates that the market values HELX at NaN times its book value.

What is the current FCF Yield for Franklin Genomic Advancements ETF (HELX) as of Mar 05 2026?

As of Mar 05 2026, Franklin Genomic Advancements ETF (HELX) has a FCF Yield of NaN%. This means that for every dollar of Franklin Genomic Advancements ETF's market capitalization, the company generates NaN cents in free cash flow.

What is the current Forward P/E ratio for Franklin Genomic Advancements ETF (HELX) as of Mar 05 2026?

As of Mar 05 2026, Franklin Genomic Advancements ETF (HELX) has a Forward P/E ratio of NaN. This means the market is willing to pay $NaN for every dollar of Franklin Genomic Advancements ETF's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Franklin Genomic Advancements ETF (HELX) as of Mar 05 2026?

As of Mar 05 2026, Franklin Genomic Advancements ETF (HELX) has a Forward P/S ratio of NaN. This means the market is valuing HELX at $NaN for every dollar of expected revenue over the next 12 months.

HELX Valuation